期刊文献+

盐酸氨溴索联合复方异丙托溴铵在老年人难治性肺炎中的应用价值 被引量:35

The application value of combination of ambroxol and fluid-micronized ipratropium bromide in treating senile refractory pneumonia
原文传递
导出
摘要 目的探讨足剂量、足频率静脉滴注盐酸氨溴索联合复方异丙托溴铵雾化吸入治疗老年人难治性肺炎的应用价值。方法2010年1月至2013年11月老年难治性肺炎患者84例,按不同治疗方法将患者分为3组,均给予抗炎及对症治疗。其中对照组28例常规吸痰及生理盐水冲洗;常规剂量组28例在对照组的基础上,给予静脉滴注盐酸氨溴索15mg,2次/d,复方异丙托溴铵雾化吸入2.5ml,1次/d;足剂量组28例在对照组基础上,应用足剂量盐酸氨溴索注射液30mg,2次/d,复方异丙托溴铵雾化吸入2.5m1,4次/d。肺部感染的严重程度采用临床肺部感染评分(CPIS)和c反应蛋白(CRP)进行描述,治疗效果以临床症状缓解时间、平均住院日及有效率进行评价。结果足剂量组的CPIS浓度治疗第5天和第10天分别为(4.82±1.21)分和(4.39±1.03)分、CRP分别为(58.11±11.12)mg/L和(50.57±12.69)mg/L,均明显低于对照组的(6.10±1.10)分和(5.36±0.95)分、(74.50±12.79)mg/L和(68.46±13.77)mg/L(均P〈0.05);较常规剂量组的(5.43±0.84)分和(5.21±0.83)分、(65.11±8.34)mg/L和(59.11±13.77)mg/L亦明显降低(均P〈0.05);足剂量组和常规剂量组治疗第10天的CPIS和CRP浓度较第5天明显下降(均P〈0.05)。足剂量组患者的临床症状缓解时间、平均住院日分别为(4.43±1.75)d和(26.32±4.92)d,常规剂量组为(5.68±2.29)d和(32.21±5.63)d,均明显低于对照组(7.79±2.74)d和(36.71±11.78)d(F=6.675、5.166,P=0.016、0.008);足剂量组的临床症状缓解时间、平均住院日较常规剂量组相比较亦明显降低(均P〈0.05)。对照组、常规剂量组和足剂量组的有效率分别为42.9%(12/28),71.4%(20/28),92.9%(26/28),其中足剂量组有效率明显高于对照组和常规剂量组(X^2=16.047、6.788,均P〈0.01),常规剂量组的有效率与对照组比较亦明显升高(X^2=4.667,P〈0.01)。结论足剂量、足频率的盐酸氨溴索联合复方异丙托溴铵雾化吸人治疗老年人难治性肺炎有较好的临床疗效。 Objective To investigate the application value of combination of ambroxol and fluid- micronized ipratropium bromide in full dose and frequency in treating senile refractory pneumonia. Methods From January 2010 to November 2013, 84 cases of elderly patients with refractory pneumonia were divided into 3 groups. On the basis of anti-inflammatory and symptomatic treatment, the control group (n= 28) received routine sputum suction and normal saline irrigation; the routine dose group (n=28) received the intravenous ambroxol 15 mg twice daily and the inhalation of 2.5 ml of nebulized ipratropium bromide once daily plus treatment in control group while full dose group ( n= 28) received intravenous ambroxol hydrochloride 30 mg three times a day and the inhalation of 2.5 ml of nebulized ipratropium bromide four times a day. The severity of pulmonary infection was described by clinical pulmonary infection score (CPIS) and C reactive protein (CRP), and therapeutic efficiency was evaluated by clinical symptom remission time, average hospitalization days and effective rate. Results At the 5 day and 10 days after treatment, the CPIS in full dose group was (4. 82± 1.21) scores and (4.39 ± 1.03 ), respectively, C-reactive protein (CRP) was ( 58.11 ± 11.12 ) mg/L and(57.57±12.69) mg/L respectively, and these CPIS and CRP values at the 5 day and 10 days were significantly lower than those in the control group (6.10 ± 1.10) scores and (5.36 ±0.95) scores, (74. 50±12. 79)mg/L and (68.46±13.77) mg/L (all P〈0. 05). The above Values were lower as compared with those [(5.43±0.84) and (5.21±0.83),(65.11±834) mg/L and (59.11±13.77) mg/L (P〈 0.05)] in routine dose group. The CPIS and CRP concentration in full dose group and routine dose group were lower at the 10 days than at the 5 days (P〈0.05). Besides, clinical symptom remission time (4.43 ±1.75)days, average hospitalization duration(26.32±4.92) days in full dose group, clinical symptom remission time (5.68± 2.29) day, average hospitalization (32.21 ± 5.63) days in conventional dose group were significantly lower than in the control group (7.79±2.74) and (36.71 ±11.78) days (P 〈 0.05 ) . Clinical manifestation, time of remission, and average hospitalization days of the full dose group were also reduced as compared with the conventional dose group (P〈0.05). The efficiency rates in the three groups of control,conventional dose and full dose were 42.9% (12/28), 71.4% (20/28), 92.9% (26/28), among which the efficiency of full dose group was significantly higher than those of the control group and the conventional dose group, (X^2=16. 047,6. 788, P〈0.01). The conventional dose group showed a higher efficiency than the control group (X^2 = 4. 667, P 〈 0.01 ) . Conclusions Combination of ambroxol and fluid-micronized ipratropium bromidet in full dose and frequency for treating senile refractory pneumonia is a useful managemen in the elderly patients.
出处 《中华老年医学杂志》 CAS CSCD 北大核心 2016年第8期854-857,共4页 Chinese Journal of Geriatrics
关键词 氨溴索 异丙托铵 肺炎 Ambroxol Ipratropium
  • 相关文献

参考文献8

二级参考文献63

  • 1邱川,李明才,武燕,李敏.慢性阻塞性肺疾病气道炎症的研究进展[J].中国呼吸与危重监护杂志,2011,10(2):196-199. 被引量:58
  • 2沈定霞,罗燕萍,崔岩,赵莉萍,白立彦.分离产金属β-内酰胺酶的铜绿假单胞菌[J].中华医院感染学杂志,2004,14(1):86-88. 被引量:109
  • 3刘又宁,陈民钧,赵铁梅,王辉,王睿,刘庆锋,蔡柏蔷,曹彬,孙铁英,胡云建,修清玉,周新,丁星,杨岚,卓建生,唐英春,张扣兴,梁德荣,吕晓菊,李胜歧,刘勇,俞云松,魏泽庆,应可净,赵峰,陈萍,侯晓娜.中国城市成人社区获得性肺炎665例病原学多中心调查[J].中华结核和呼吸杂志,2006,29(1):3-8. 被引量:788
  • 4慢性阻塞性肺疾病诊治指南(2007年修订版)[J].中华结核和呼吸杂志,2007,30(1):8-17. 被引量:8235
  • 5许建英,李筱妍,杜永成,杨丽莉,王淑峰,王红.慢性阻塞性肺疾病急性加重期病原学与肺功能关系的研究[J].中国呼吸与危重监护杂志,2007,6(2):88-92. 被引量:21
  • 6[1]Gillissen A, Nowak D. Characterization of N-acetylcysteine and ambroxol in anti-oxidant therapy. Respir Med, 1998, 92:609-623.
  • 7[2]Teramoto S, Suzuki M, Ohga E, et al. Effects of ambroxol on spontaneous or stimulated generation of reactive oxygen species by bronchoalveolar lavage cells harvested from patients with or with-out chronic obstructive pulmonary diseases. Pharmacology,1999, 59:135-141.
  • 8[3]Gillissen A, Bartling A, Schoen S, et al. Antioxidant function of ambroxol in mononuclear and polymorphonuclear cells in vitro. Lung, 1997, 175:235-242.
  • 9[4]Park NH, Han ES, Lee CS, et al. The inhibitory effect of ambroxol on respiratory burst, de granulation and cytosolic Ca2+ change in degraded immunoglobulin G-activated neutrophils. Pharmacol Toxicol, 1999, 84: 81-87.
  • 10[5]Pfeifer S, Zissel G, Kienast K, et al. Reduction of cytokine release of blood and bronchoalveolar mononuclear cells by ambroxol. EurJ Med Res, 1997, 2:129-132.

共引文献3408

同被引文献237

引证文献35

二级引证文献190

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部